Wedbush analyst Robert Driscoll raised the firm’s price target on Arvinas (ARVN) to $11 from $9 and keeps a Neutral rating on the shares following quarterly results and corporate updates. The firm notes data remains on track for LRRK2 degrader ARV-102 in Parkinson’s disease patients, which will be presented in oral presentation at the International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders in March 2026. While Wedbush remains on the sidelines pending further clinical insights across Arvinas’ Phase 1 pipeline, the firm sees a busy year of readouts that could allow it to become more constructive.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARVN:
- Arvinas price target raised to $19 from $14 at Evercore ISI
- Arvinas price target raised to $20 from $16 at Piper Sandler
- Arvinas: Strong Pipeline Momentum, De-Risked Cash Runway, and Attractive Risk‑Reward Support Buy Rating
- Arvinas Earnings Call: High Science, Tight Cash
- Balancing Emerging Clinical Momentum and Commercial Uncertainty: Maintaining a Hold on Arvinas Ahead of Key 2026 Readouts